Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
M. MacKintosh, C. Tower, B. Clarke & S. Vause. (2010) Anhydramnios secondary to angiotensin II converting enzyme inhibitors: A reversible condition?. Journal of Obstetrics and Gynaecology 30:8, pages 865-866.
Read now
Read now
Jeffrey A Kramer. (2008) Designing safe drugs: what to consider?. Expert Opinion on Drug Discovery 3:7, pages 707-713.
Read now
Read now
KathrynZ. Guyton, Stanley Barone$suffix/text()$suffix/text(), RebeccaC. Brown, SusanY. Euling, Jennifer Jinot & Susan Makris. (2008) Mode of Action Frameworks: A Critical Analysis. Journal of Toxicology and Environmental Health, Part B 11:1, pages 16-31.
Read now
Read now
Alan R. Boobis, John E. Doe, Barbara Heinrich-Hirsch, M. E. (Bette) Meek, Sharon Munn, Mathuros Ruchirawat, Josef Schlatter, Jennifer Seed & Carolyn Vickers. (2008) IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans. Critical Reviews in Toxicology 38:2, pages 87-96.
Read now
Read now
Articles from other publishers (22)
Hui-Kim Yap & Perry Yew-Weng Lau. 2023. Pediatric Kidney Disease. Pediatric Kidney Disease
373
404
.
Wenyue Zheng, Erkang Tian, Zhen Liu, Changhan Zhou, Pei Yang, Keyue Tian, Wen Liao, Juan Li & Changyu Ren. (2022) Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective. Frontiers in Pharmacology 13.
Crossref
Crossref
Kendall S. Frazier. (2021) The Impact of Functional and Structural Maturation of the Kidney on Susceptibility to Drug and Chemical Toxicity in Neonatal Rodents. Toxicologic Pathology 49:8, pages 1377-1388.
Crossref
Crossref
Jean‐Yu Hwang, Wei‐Chih Kan, Yao‐Bin Liu, Lea‐Yea Chuang, Jinn‐Yuh Guh, Yu‐Lin Yang & Jau‐Shyang Huang. (2019) Angiotensin‐converting enzyme inhibitors attenuated advanced glycation end products‐induced renal tubular hypertrophy via enhancing nitric oxide signaling. Journal of Cellular Physiology 234:10, pages 17473-17481.
Crossref
Crossref
Kendall S. Frazier. (2017) Species Differences in Renal Development and Associated Developmental Nephrotoxicity. Birth Defects Research 109:16, pages 1243-1256.
Crossref
Crossref
E. Koch & S. Plassmann. 2017. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. A Comprehensive Guide to Toxicology in Nonclinical Drug Development
7
38
.
Jude S. Morton, Christy-Lynn Cooke & Sandra T. Davidge. (2016) In Utero Origins of Hypertension: Mechanisms and Targets for Therapy. Physiological Reviews 96:2, pages 549-603.
Crossref
Crossref
Hui-Kim Yap & Perry Yew-Weng Lau. 2016. Pediatric Kidney Disease. Pediatric Kidney Disease
391
418
.
Norikazu Ueki, Satoru Takeda, Daisuke Koya & Keizo Kanasaki. (2015) The Relevance of the Renin-Angiotensin System in the Development of Drugs to Combat Preeclampsia. International Journal of Endocrinology 2015, pages 1-12.
Crossref
Crossref
J Koo & A Zavras. (2013) Antiepileptic drugs (AEDs) during pregnancy and risk of congenital jaw and oral malformation. Oral Diseases 19:7, pages 712-720.
Crossref
Crossref
Young Joo Jeon, Ji Hyang Kim, Bo Eun Lee, HyungChul Rah, Ji Eun Shin, Hojeong Kang, Dong Hee Choi, Tae Ki Yoon, Woo Sik Lee, Sung Han Shim & Nam Keun Kim. (2013) Association between Polymorphisms in the Renin-Angiotensin System Genes and Prevalence of Spontaneously Aborted Fetuses. American Journal of Reproductive Immunology 70:3, pages 238-245.
Crossref
Crossref
Leeann M. Bellamy, Adam P. W. Johnston, Michael De Lisio & Gianni Parise. (2010) Skeletal muscle-endothelial cell cross talk through angiotensin II. American Journal of Physiology-Cell Physiology 299:6, pages C1402-C1408.
Crossref
Crossref
Dianne B. McKay & Michelle Josephson. (2010) Pregnancy in renal transplant recipients. Dialysis & Transplantation 39:11, pages 472-475.
Crossref
Crossref
Roland Lennestål, Petra Otterblad Olausson & Bengt Källén. (2009) Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. European Journal of Clinical Pharmacology 65:6, pages 615-625.
Crossref
Crossref
A.Y. Ponstein-Simarro Doorten, J.A.G. vd Wiel & D. Jonker. (2009) Safety evaluation of an IPP tripeptide-containing milk protein hydrolysate. Food and Chemical Toxicology 47:1, pages 55-61.
Crossref
Crossref
Aarif Y. Khakoo, Richard L. Sidman, Renata Pasqualini & Wadih Arap. (2008) Does the Renin-Angiotensin System Participate in Regulation of Human Vasculogenesis and Angiogenesis?. Cancer Research 68:22, pages 9112-9115.
Crossref
Crossref
U. Martin, M. A. Foreman, J. C. Travis, D. Casson & J. J. Coleman. (2008) Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. Journal of Clinical Pharmacy and Therapeutics 33:5, pages 507-511.
Crossref
Crossref
Jaime L. Frías & Enid Gilbert-Barness. (2008) Human Teratogens: Current Controversies. Advances in Pediatrics 55:1, pages 171-211.
Crossref
Crossref
Hui-Kim Yap & Perry Yew-Weng Lau. 2008. Comprehensive Pediatric Nephrology. Comprehensive Pediatric Nephrology
179
193
.
Rebecca L Branch & Una Martin. (2007) Adverse effects of angiotensin-converting enzyme inhibitors and Angiotensin-II receptor blockers in pregnancy. Adverse Drug Reaction Bulletin &NA;:246, pages 943-946.
Crossref
Crossref
Jeffrey A. Kramer, John E. Sagartz & Dale L. Morris. (2007) The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nature Reviews Drug Discovery 6:8, pages 636-649.
Crossref
Crossref
C. Sernia, H. Huang, K. Nguyuen, Y-H. Li, S. Hsu, M. Chen, N. Yu & M. Forwood. 2007. Frontiers in Research of the Renin-Angiotensin System on Human Disease. Frontiers in Research of the Renin-Angiotensin System on Human Disease
179
195
.